Craig Lindsley

  • Vanderbilt University

    WCNDD-developed Parkinson’s drug to enter next phase of clinical trial

    A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read More

    Apr. 4, 2022

  • Vanderbilt University

    Vanderbilt extends its longest ongoing drug discovery agreement with pharmaceutical company through 2023

    Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. The initial agreement was signed in November… Read More

    Dec. 22, 2021

  • Vanderbilt University

    Deciphering the Circuits in Neuroscience Research

    Around 500 million people around the world are affected by poor mental health including disorders such as depression, schizophrenia, bipolar disease and dementia with a significant impact on quality of life as well as associated social and economic consequences.1 Boehringer Ingelheim is dedicated to redefining the management of mental health. Read More

    Dec. 7, 2021